Sep 30, 2019
Neovasc's Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference
Sep 23, 2019
Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina to be Featured at TCT 2019 Conference
Sep 16, 2019
Neovasc Announces Changes to its Board of Directors
Sep 04, 2019
Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Sep 03, 2019
The European Society of Cardiology Includes Neovasc Reducer(TM) for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes
Aug 22, 2019
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Aug 07, 2019
Neovasc Announces Second Quarter 2019 Financial Results
Aug 05, 2019
Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference
Aug 02, 2019
Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th
Jul 17, 2019
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency
Jul 16, 2019
Neovasc Provides Further Update on Reducer(TM) Program for Treatment of Refractory Angina
Jul 15, 2019
Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves
Jul 12, 2019
Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA
Jun 28, 2019
Neovasc Announces Effective Date of Share Consolidation
Jun 27, 2019
Neovasc Announces Presentations on Tiara(TM) for Treatment of Mitral Regurgitation and Reducer(TM) for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference
Jun 25, 2019
Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule
Jun 17, 2019
Tiara(TM) Featured in Presentation at 11th Annual TVT 2019
Jun 07, 2019
Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million
Jun 04, 2019
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer(TM)
May 28, 2019
Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer(TM)